ICU Medical, Inc. (NASDAQ:ICUI) Director Elisha W. Finney Sells 600 Shares

ICU Medical, Inc. (NASDAQ:ICUI) Director Elisha W. Finney sold 600 shares of the stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $138.92, for a total transaction of $83,352.00. Following the completion of the transaction, the director now owns 3,252 shares of the company’s stock, valued at $451,767.84. This represents a 15.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

ICU Medical Price Performance

Shares of NASDAQ ICUI opened at $130.75 on Thursday. ICU Medical, Inc. has a twelve month low of $100.91 and a twelve month high of $196.26. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The firm has a 50-day moving average of $140.42 and a two-hundred day moving average of $153.32. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of -28.61 and a beta of 0.87.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, beating the consensus estimate of $1.23 by $0.49. The business had revenue of $599.49 million during the quarter, compared to analyst estimates of $574.15 million. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.96 earnings per share. As a group, analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ICU Medical

Institutional investors and hedge funds have recently modified their holdings of the stock. Norges Bank acquired a new position in shares of ICU Medical in the 4th quarter worth $40,151,000. The Manufacturers Life Insurance Company boosted its position in shares of ICU Medical by 992.1% in the 1st quarter. The Manufacturers Life Insurance Company now owns 130,762 shares of the medical instruments supplier’s stock valued at $18,158,000 after purchasing an additional 118,789 shares during the period. MetLife Investment Management LLC increased its stake in ICU Medical by 850.4% in the 1st quarter. MetLife Investment Management LLC now owns 123,041 shares of the medical instruments supplier’s stock worth $17,085,000 after purchasing an additional 110,095 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in ICU Medical by 18.5% during the 1st quarter. Ameriprise Financial Inc. now owns 693,711 shares of the medical instruments supplier’s stock worth $96,326,000 after buying an additional 108,493 shares during the period. Finally, GAMMA Investing LLC raised its holdings in ICU Medical by 17,559.7% during the 1st quarter. GAMMA Investing LLC now owns 99,424 shares of the medical instruments supplier’s stock worth $138,060,000 after buying an additional 98,861 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Tuesday, April 8th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a report on Sunday. KeyCorp decreased their price target on ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research note on Monday, April 21st. Finally, Raymond James lowered their price target on ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating on the stock in a research report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $192.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.